Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Brystkræftbehandlingen er slut, men søvnen er ikke vendt tilbage: Smartphone-apps skal testes på 747 kvinder
Det er ikke nok at høre gisp: Hvorfor et nyt studie tilføjer smartphone-video til nødopkald
Hvad en udånding kan fortælle: Ny test skal afprøves på 1.000 patienter med mistanke om mave- og tarmkræft
Før de første hukommelsesproblemer: Roche vil teste lægemiddel på personer med Alzheimers-biomarkører
A Diaper Photo Could Help Spot Liver Disease in Babies: UK Tests AI
Tumor forbliver efter behandling: Ny kombination skal testes på 1.000 patienter med aggressiv brystkræft
HIV-behandling uden daglige piller: Gilead tester ny langtidsvirkende behandling i to fase 3-studier

Kommende kliniske forsøg

Clinical Research Jobs

More jobs

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

Abonner